BioSpace News Archive

Non-invasive cardiac assessment company Sensydia announced today that it has completed its 225-subject development study at the University of Pittsburgh Medical Center (UPMC).

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a company developing treatments for severe neurodegenerative diseases, today announced that Health Canada approved the commencement of patient enrollment in Canada for the Company’s Phase 2b PARADIGM study of its combination therapy PrimeC for the treatment of amyotrophic lateral sclerosis (ALS).

Vistagen (NASDAQ: VTGN) today announced it will host a conference call and webcast on Tuesday, February 7, 2023, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report financial results for its fiscal year 2023 third quarter ended December 31, 2022 and provide a corporate update.

ACG, a leading supplier of fully integrated manufacturing solutions to the global pharmaceutical and nutraceutical industries, is pleased to announce the appointment of Rafael Costa as Vice President for the Americas region.

3M unveils its new medical adhesive that can stick to the skin for up to 28 days and is intended for use with a wide array of health monitors, sensors, and long-term medical wearables.

Lucius Partners, LLC announced the addition of Centaur Bio, Inc. to the company’s portfolio.

Global LAG-3 Inhibitor Market, Drug Sales, Price & Clinical Trials Insight 2028 Report highlights:

Advisors bring large-scale medical research, statistical, epidemiological, operational and funding expertise to the company

Dana Walker, MD, MSCE, our vice president and Genitourinary Cancers Development Lead, sheds light on the importance of ongoing GU cancer research, the unmet needs for patients with GU tumors and where we go from here to offer hope to even more people impacted by cancer.

Chinook Therapeutics, Inc. announced that the Compensation Committee of the Company’s Board of Directors approved new employment inducement grants of stock options to purchase a total of 28,957 shares of common stock and restricted stock units for 14,478 shares with a grant date of January 31, 2023 for five new employees pursuant to the Company’s 2022 Equity Inducement Plan.